After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sarepta will start testing a new gene therapy for limb-girdle muscular dystrophy.

A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped ...

Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations ...

Last year was a standout one for Amgen. No fewer than 10 of its medications posted double-digit percentage sales growth. High cholesterol treatment Repatha vaulted higher with a 36% increase over ...

Nasa says there is a small chance a recently spotted asteroid could collide with the Moon. Studying it can inform our understanding of the Earth's past and our future. Each year, according to Nasa ...

Additionally, Piper Sandler has maintained its Overweight rating on Amgen with a price target of $329, citing significant volume growth for key drugs like Repatha and Tezspire. Repatha saw a 44% ...

The latest trading session saw Amgen (AMGN) ending at $310.09, denoting a +1.44% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 4.84%.

It has many blockbuster drugs in its portfolio, including Repatha (cholesterol) and Prolia (osteoporosis), which generated a combined $6.6 billion in sales in 2024. On top of all this, Amgen has a ...

I eventually went on Repatha (an injectable medication—not a statin—that binds to a protein called PCSK9 and prevents the protein from binding with and breaking down cholesterol receptors on ...

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung ...